Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...

I analyze the 50 Fortune World's Most Admired Companies, focusing on dividend-paying stocks and their yield-based investment ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Cogent Biosciences, Inc. is a Strong Buy after trial data for bezuclastinib & market growth potential in systemic ...

Listen and subscribe to Stocks In Translation on Apple Podcasts, Spotify, or wherever you find your favorite podcast.Nvidia’s (NVDA) explosive growth is doing more than lifting portfolios - it’s ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...

This was the stock's third consecutive day of losses.

This was the stock's second consecutive day of losses.

Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade.